RUA Life Sciences plc announced that Iain Anthony, Director of Clinical and Regulatory Affairs has tendered his resignation from the Company in order to accept an opportunity elsewhere within the industry. Iain joined RUA in November 2021 and has overseen the building of the Regulatory and Quality teams together with further development of the vascular graft device and was instrumental in undertaking the Q-Sub process with the FDA which has recently concluded succesfully. Iain will step down from the board with immediate effect but will continue in his role as an employee for an appropriate handover period while the Board looks for his successor.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.38 GBX | +2.25% | +5.81% | +15.48% |
Apr. 05 | RUA Life Sciences expects flat annual revenue on strong second half | AN |
Apr. 05 | RUA Life Sciences plc Provides Revenue Guidance for the Year Ended 31 March 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.48% | 8.86M | |
+7.84% | 218B | |
+7.35% | 184B | |
+13.04% | 135B | |
+26.03% | 107B | |
-1.33% | 62.38B | |
+11.80% | 51.37B | |
+4.81% | 50.9B | |
+0.30% | 40.87B | |
+2.78% | 36.28B |
- Stock Market
- Equities
- AOR Stock
- News RUA Life Sciences plc
- RUA Life Sciences plc Announces Iain Anthony, Director of Clinical and Regulatory Affairs Tenders His Resignation